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ABSTRACT 
 
Introduction: The Enhanced Recovery After Surgery (ERAS) protocol is an evidence-based, 
multidisciplinary peri-operative care model that has been shown to reduce complications and 
hospital length of stay (LOS), improve cardiopulmonary function, and lead to earlier return of 
bowel function. While some thoracic ERAS studies have been inconclusive, others have 
shown that ERAS improves patient outcomes after lung resections and provides more cost-
effective care. We aimed to investigate the effect of ERAS, in comparison to conventional 
care, on lung resection outcomes at the University of North Carolina (UNC) Hospitals. 
 
Methods: In this retrospective cohort study, adult patients undergoing lung resections (wedge 
resection, segmentectomy, lobectomy, and bilobectomy) during the pre-ERAS (April 2014-
September 2015) and post-ERAS (January 2016-May 2017) periods were identified from the 
UNC thoracic surgery database. Resections performed during the wash-in period (October-
December 2015) were excluded. Relevant demographic, pre-operative, anesthesia, and 
surgical variables were collected. Pre- and post-ERAS cohorts were compared in terms of 
hospital LOS, post-operative complications, 30-day readmission and mortality. 
 
Results: We identified 264 patients, half of which were exposed to ERAS. Pre- and post-
ERAS groups were similar with respect to age, race, and comorbidities. There was no 
significant difference in hospital LOS, complications, or 30-day readmission between groups. 
There were only two cases of 30-day post-operative mortality in the post-ERAS group. Of the 
163 patients in both groups who had hospital LOS greater than 3 days, 45 (28%) had 
pulmonary complications, half of which were prolonged air leaks for greater than 5 days. 
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Conclusions: Median hospital LOS, complications, and 30-day readmission did not differ 
significantly between the pre- and post-ERAS groups. Thoracic ERAS protocols should 
include interventions to reduce air leak and consider discharging patients with chest tubes 
placed to a Heimlich valve. ERAS has been shown to improve patient satisfaction, and this 
warrants further studies. 
 
Abstract word count: 298 words 
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INTRODUCTION 
 
In the 1990s, Henrik Kehlet developed the Enhanced Recovery After Surgery (ERAS) 
protocol, an evidence-based, multidisciplinary peri-operative care model. Key principles of 
ERAS protocols include the following: pre-operative counseling; pre-operative nutrition 
(minimizing peri-operative fasting and carbohydrate loading up to 2 hours pre-operatively); 
standardized multimodal anesthetic and analgesic regimens (epidural and non-opioid 
analgesia); optimized antibiotic and thromboembolic prophylaxis; and early post-operative 
mobilization. This model has been shown to reduce complications and hospital length of stay 
(LOS), improve cardiopulmonary function, and lead to earlier return of bowel function and 
resumption of normal activity. The ERAS protocol was first adapted by the colorectal surgery 
discipline and has since been utilized by other surgical specialties, including vascular 
surgery, urologic surgery, and thoracic surgery1,2. 
 
In the field of thoracic surgery, the prototypical ERATS (Enhanced Recovery After Thoracic 
Surgery) pathway involves three phases. The first is the pre-operative phase which includes 
the following: pre-operative visit and assessment; patient education and explanation of 
ERAS; smoking cessation; pre-operative rehabilitation; admission on day of surgery; pre-
operative carbohydrate drink; and avoidance of sedative pre-anesthetic medication. Next, the 
peri-operative phase incorporates prophylactic antibiotics, regional anesthesia with 
paravertebral catheters, avoidance of crystalloid overload, intra-operative warming, venous 
thromboembolism prophylaxis, avoidance of urinary catheter, minimally-invasive surgery 
(such as video-assisted thoracoscopic surgery [VATS] where possible), and single chest 
drain). Finally, the post-operative phase comprises of avoidance of post-operative 
intravenous fluids, avoidance of opiate analgesia, early feeding, targeted post-operative 
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nausea and vomiting therapy, use of incentive spirometry (pulmonary toileting), early 
mobilization within 24 hours, and early chest tube and urinary catheter removal2,3. 
 
In October 2015, the UNC Department of Anesthesiology gradually began to implement an 
ERAS pathway specific to the UNC Division of Cardiothoracic Surgery’s Thoracic Surgery 
service. Since this ERAS pathway was fully implemented in January 2016, both UNC 
cardiothoracic anesthesiologists and surgeons have collected preliminary data and noted 
increased patient satisfaction with care, decreased peri-operative complications, decreased 
hospital LOS, and improved use of hospital resources4,5. 
 
Although the use of ERAS in lung resections began almost 20 years ago, ERATS protocols 
have not been studied as extensively as ERAS pathways in colorectal surgery. Initially, most 
of the evidence for ERATS was published in case-series; the lack of a control group in these 
studies increases risk of bias and limits the ability to attribute improvements in care to 
ERATS6-8. While some recent thoracic ERAS studies in the literature have been 
inconclusive9, others have shown that ERAS improves patient outcomes after lung resections 
and provides more cost-effective care10,11. Objectives of this study were to (1) investigate the 
effect of ERAS, in comparison to conventional care, on lung resection outcomes at UNC 
Hospitals, and (2) determine the predictive demographic, pre-operative, anesthesia, or 
surgical factors that are associated with decreased hospital LOS, morbidity, and mortality. 
 
METHODS 
 
Study design: 
In this retrospective cohort study, adult patients (age >18 years) undergoing lung resections 
(wedge resection, segmentectomy, lobectomy, and bilobectomy) during the pre-ERAS (April 
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2014-September 2015) and post-ERAS (January 2016-May 2017) periods were identified 
from the UNC thoracic surgery database. Only a patient’s first thoracic surgery within this 
timeframe was eligible for inclusion. Resections performed during the ERAS wash-in period 
(October-December 2015) were excluded. Patients who simultaneously underwent 
esophagectomy (n=2), pneumonectomy (n=1), coronary artery bypass grafting (CABG, n=1) 
and trauma patients (n=4) were excluded. 
 
The following demographic variables and baseline clinical characteristics were abstracted 
from the electronic health record (EHR): age, race, gender, weight, body mass index (BMI), 
comorbidities (hypertension, steroid use, congestive heart failure, coronary artery disease, 
peripheral vascular disease, pre-operative chemotherapy or radiation, prior cardiothoracic 
surgery, insulin-dependent diabetes mellitus, and renal insufficiency), smoking status, 
pulmonary function test (PFT) results, Karnofsky performance index12, and thoracic revised 
cardiac risk index (ThRCRI, which assigns points for history of ischemic heart disease, 
cerebrovascular accident, creatinine >2, and pneumonectomy13). Anesthesia-related variables 
collected included the following: American Society of Anesthesiologists (ASA) score, 
baseline pulse oximetry measurement at room air, pre-operative laboratory values 
(hemoglobin, creatinine, bicarbonate), pre-operative medications (acetaminophen, pregabalin, 
celecoxib), total peri-operative anesthesia time, intra-operative nadir pulse oximetry 
measurement, intra-operative blood transfusion, total intra-operative crystalloid and colloid 
fluids, intra-operative medications (ketorolac, dexamethasone, vasopressin, norepinephrine), 
amount of intra-operative opioids (fentanyl, hydromorphone, oxycodone) in terms of 
morphine equivalents, intercostal nerve block (ICB) medications (bupivacaine [Marcaine], 
bupivacaine liposome injectable suspension [Exparel], or both), type of regional block (ICB, 
epidural, or both), and post-operative extubation in operating room (OR). The following 
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thoracic surgery-related variables were collected: procedure (wedge resection, 
segmentectomy, lobectomy, bilobectomy), primary diagnosis (benign lung disease, lung 
cancer, or metastatic lung cancer), lung cancer clinical and pathological staging (if 
applicable), and total surgery time. 
 
Pre- and post-ERAS patients were compared in terms of hospital LOS, total number of post-
operative complications, 30-day readmission and mortality. Pulmonary, cardiovascular, 
urologic, infectious, hematologic, gastrointestinal, neurologic, and miscellaneous 
complications were as defined by the Society of Thoracic Surgeons (STS)14 (Table 1). 
 
Statistical Analyses: 
Patient demographics, surgical characteristics, and post-operative outcomes were compared 
between pre- and post-ERAS patients using Fisher’s exact and Wilcoxon-Mann-Whitney 
tests, where appropriate. A p-value <0.05 was considered statistically significant.  
 
Cox proportional hazard regression was used to estimate the effect of ERAS implementation 
on inpatient complications and 30-day readmission. For inpatient complications, patients 
were followed until discharge, and for 30-day readmission, patients were followed for up to 
30-days post-discharge. Multivariable hazard regression was used to estimate the effect of 
ERAS on patient outcomes, after adjusting for age, sex, steroid use prior to surgery, ThRCRI, 
intra-operative crystalloids, intra-operative colloids, and intra-operative morphine 
equivalents. Age, crystalloids, colloids, and morphine equivalents were modeled as restricted 
cubic splines to allow for the most flexibility. Due to low incidence, some outcomes were 
unable to be modeled. 
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Crude and multivariable linear regression was used to assess the effect of ERAS on average 
length of stay after surgery. Multivariable models were adjusted for the same variables 
described above. 
 
All analyses were performed in Stata SE version 15.115 (College Station, Texas). 
 
Ethics Approval: 
The institutional review board of the University of North Carolina at Chapel Hill provided 
ethical approval of the study (IRB# 15-1841).  
 
RESULTS 
 
Patient Baseline Characteristics: 
Overall, 264 patients were included; 133 (50%) underwent surgery pre-ERAS and 131 (50%) 
underwent surgery post-ERAS implementation. In the pre-ERAS group, median age was 64 
years, 50% were male, and median body mass index (BMI) was 27 kg/m2. In terms of race, 
100 (75%) were white, 27 (20%) were black, and 6 (5%) were of another race. For pre-
operative PFTs, median forced expiratory volume in 1 second (FEV1) was 83%, and median 
diffusing capacity for carbon monoxide (DLCO) was 70%. Median Karnofsky performance 
index was 100. Regarding smoking status, 35 (26%) were never smokers, 69 (52%) were 
former smokers, 29 (22%) were current smokers; 34 (26%) smoked within four weeks of 
surgery. For primary diagnosis, 25 (19%) had benign lung disease, 77 (58%) had lung cancer, 
and 31 (23%) had metastatic lung cancer (Table 2). 
 
In the post-ERAS group, median age was 61, 38% were male, and median BMI was also 27 
kg/m2. In terms of race, 92 (70%) were white, 28 (21%) were black, 11 (8%) were of another 
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race. For pre-operative PFTs, median FEV1 was 83%, and median DLCO was 75%. Median 
Karnofsky performance index was 90. Regarding smoking status, 36 (27%) were never 
smokers, 72 (55%) were former smokers, and 23 (18%) were current smokers; 29 (22%) 
smoked within four weeks of surgery. For primary diagnosis, 24 (18%) had benign lung 
disease, 69 (53%) had lung cancer, and 32 (24%) had metastatic lung cancer (Table 2).  
 
Pre- and post-ERAS groups did not differ significantly in terms of age, race, BMI, 
comorbidities, smoking status, smoking within four weeks of surgery, pre-operative 
chemotherapy or radiation, history of prior cardiothoracic surgery, primary diagnosis, PFTs, 
Karnofsky performance index, ASA score, or ThRCRI. The two groups did, however, differ 
significantly with respect to gender (p=0.05) and history of steroid use (p=0.001); the pre-
ERAS group had a higher percentage of males (50% vs. 38%), and fewer patients were on 
steroids compared to the post-ERAS group (35% vs 56%) (Table 2).  
 
Intra-operative Characteristics: 
In the pre-ERAS group, 85 (64%) had wedge resections, 0 (0%) had segmentectomies, 46 
(35%) had lobectomies, and 2 (2%) had bilobectomies. Median surgery time was 121 
minutes, and median anesthesia time was 159 minutes. Very few patients received the three 
pre-operative medications: acetaminophen (5%), pregabalin (4%), and celecoxib (1). In terms 
of intra-operative medications, 3 (2%) received ketorolac, 44 (33%) received dexamethasone, 
9 (7%) received vasopressin, and 1 (1%) received norepinephrine. Median volume of 
crystalloids received was 2000 milliliters (mL), median volume of colloids received was 0 
mL, and median amount of morphine equivalents received was 25 mg. For type of regional 
block, 90 (68%) received an ICB, 0 (0%) had an epidural, and 43 (32%) had both. All pre-
ERAS patients received bupivacaine (Marcaine) as their ICB (Table 3).  
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In the post-ERAS group, 74 (56%) had wedge resections, 1 (1%) had a segmentectomy, 56 
(43%) had lobectomies, and 0 (0%) had bilobectomies. Median surgery time was 119 
minutes, and median anesthesia time was 173 minutes. Majority of patients received the three 
pre-operative medications: acetaminophen (78%), pregabalin (65%), and celecoxib (56%). In 
terms of intra-operative medications, 26 (20%) received ketorolac, 69 (53%) received 
dexamethasone, 51 (39%) received vasopressin, and 18 (14%) received norepinephrine. 
Median volume of crystalloids received was 800 mL, median volume of colloids received 
was 250 mL, and median amount of morphine equivalents received was 20 mg. For type of 
regional block, 102 (78%) had an ICB, 0 (0%) had an epidural, and 29 (22%) had both. 
Regarding type of ICB, 37 (28%) had bupivacaine (Marcaine), 61 (47%) had bupivacaine 
liposome injectable suspension (Exparel), and 33 (25%) had both (Table 3). 
 
The pre- and post-ERAS groups differed significantly in terms of all three pre-operative 
medications (p<0.0001), robotic surgery (p<0.0001), all four intra-operative medications 
(p=0.002 for dexamethasone and p<0.0001 for others), type of ICB (p<0.0001), total 
crystalloids (p<0.0001), total colloids (p<0.0001), and morphine equivalents (p<0.0001). The 
post-ERAS group had significantly higher use of all of these medications. However, the two 
groups did not differ significantly with respect to procedure, surgery or anesthesia time, or 
regional block type (Table 3). 
 
Post-operative Outcomes: 
In the pre-ERAS group, median hospital LOS was 4 days, total number of post-operative 
complications was 57 (36 patients had complications [27%]), 11 (8%) were readmitted to the 
hospital within 30 days of surgery, and 0 (0%) died within 30 days of surgery (Table 4).  
 8 
 
In the post-ERAS group, median hospital LOS was 4 days, total number of post-operative 
complications was 56 (44 patients had complications [34%]), 13 (10%) were readmitted to 
the hospital within 30 days of surgery, and 2 (2%) died within 30 days of surgery (Table 4).  
 
The pre- and post-ERAS groups did not differ significantly in terms of median hospital LOS, 
post-operative complications, 30-day readmission and mortality (Table 4). In a subgroup 
analysis, median hospital LOS was 3 days for both wedge resection groups, and 5 days for 
both lobectomy groups. Similarly, there was no significant difference in the total number of 
post-operative complications and 30-days readmission rates within the wedge resection and 
lobectomy subgroups. 
 
Of the 163 patients in both groups who had hospital LOS greater than 3 days, 45 (28%) had 
pulmonary complications, half of which were prolonged air leaks for greater than 5 days. 
 
The Effect of ERAS on LOS and Associated Predictors: 
When compared to pre-ERAS implementation, ERAS implementation did not have a 
significant effect on post-operative complications, hospital LOS, or 30-day readmission rates. 
 
When adjusted for sex, age, prior steroid use, thoracic revised cardiac risk index, intra-
operative crystalloids, intra-operative colloids, and intra-operative morphine equivalents, the 
adjusted hazard ratio (HR) for any post-operative complications was 1.23 (95% confidence 
interval [CI], 0.61-2.48; p=0.56) (Table 5). When adjusted for the same variables listed 
above, the adjusted HR for 30-day readmissions was 2.25 (95% CI, 0.61-8.29; p=0.22) 
(Table 5). When adjusted for the same variables listed above, the adjusted change in estimate 
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(CIE) of ERAS implementation on hospital LOS was 0.15 (95% CI, -1.43-1.73; p=0.85) 
(Table 5). 
 
DISCUSSION 
 
In this retrospective cohort study, patients who underwent lung resections in the pre- and 
post-ERAS had similar baseline characteristics and only differed significantly with respect to 
gender and history of steroid use. In terms of intra-operative characteristics, the two groups 
differed significantly in terms of all three pre-operative medications, all four intra-operative 
medications, all three types of ICB, total crystalloids, total colloids, and total morphine 
equivalents given; all of these variables correspond with key components of the ERAS 
protocol, such as goal-directed fluid management and multimodal anesthetic and analgesic 
regiments (with judicious use of opioid pain medications). ERAS also requires careful 
consideration of blood transfusions, and none of the study patients underwent intra-operative 
blood transfusions.  
 
As ERAS protocols prefer shorter incisions and use of laparoscopic approach when possible, 
the majority of our patients had minimally-invasive VATS procedures16 (only three in each 
group underwent conversion to thoracotomy). Fifteen patients in the post-ERAS group 
underwent robotic-assisted thoracoscopic surgery (RATS), which has been shown to reduce 
hospital LOS, 30-day mortality, and post-operative blood transfusion when compared to 
VATS and thoracotomy procedures17. These minimally-invasive surgical techniques are also 
important from a cost perspective, as studies have shown that the average cost of inpatient 
procedures (wedge resections and lobectomies) with VATS and RATS are both lower than 
that of an open thoracotomy approach18-20. One cost-minimization analysis demonstrated that 
utilizing VATS for the 50,000 lobectomies performed in the United States each year, 
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compared to open lobectomy via posterolateral thoracotomy, would result in cost savings of 
approximately $100 million20. 
 
Median hospital LOS, total number of post-operative complications, 30-day readmission and 
mortality rates did not differ significantly between the pre- and post-ERAS groups. There 
was no significant difference in the total number of post-operative complications and 30-day 
readmission rates within the wedge resection and lobectomy subgroups as well. There were 
only two cases of post-operative mortality in the post-ERAS group. 
 
Median hospital LOS was four days for both groups overall, three days for both VATS 
wedge resection groups, and five days for both VATS lobectomy groups; these medians are 
comparable to, or even lower than, national medians demonstrated in other studies19,21-23. 
This result was consistent with a recent study by Brunelli et al., which showed no statistically 
significant benefit from ERAS implementation on outcomes such as hospital LOS, 
cardiopulmonary complications, 30- and 90-day mortality, and readmissions9. However, our 
study results contradict two other recent studies: Madani et al. and Paci et al. Both found that 
ERAS was associated with significantly decreased hospital LOS and complications with no 
difference in readmission. In addition, one study also found that ERAS in lung resections was 
associated with societal cost savings ($4,396 Canadian dollars)10,11. 
 
For our study, there are a few potential explanations for why rates of healthcare utilization 
and complications were not significantly lower in the post-ERAS group compared with the 
pre-ERAS group. Firstly, our data represents a snapshot of ERAS implementation for lung 
resections at a single academic medical center, and our sample size is relatively small. 
Secondly, the UNC Thoracic Surgery service had low post-operative complication rates 
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before ERAS implementation, and the median hospital LOS was already consistent with the 
national median19,21-23; thus, it would be difficult to notice a significant difference in 
outcomes associated with ERAS implementation. Of note, the UNC Thoracic Surgery service 
even won the 2018 UNC Excellence in Quality Award; concurrent efforts to improve patient 
safety and surgical outcomes render it more challenging to determine the overall effect of 
ERAS during this time period24.  
 
Next, pre-ERAS care may have already involved sufficient ERAS components to result in 
good outcomes. For example, one of the key elements of ERAS in thoracic surgery is the 
utilization of VATS, and almost all of our pre-ERAS patients had VATS procedures. 
Similarly, pre-operative counseling and antibiotic prophylaxis are variables that were also 
present before ERAS. In addition, minimally-invasive VATS lung resections may already be 
associated with low procedural risk and an uncomplicated recovery, and ERAS may not be 
required9.  
 
Furthermore, pulmonary air leaks often prolong hospital LOS and thus may affect the ability 
to measure differences in hospital LOS before and after ERAS. Of the 163 patients in both 
groups who had hospital LOS greater than 3 days, 45 (28%) had pulmonary complications, 
half of which were prolonged air leaks (greater than 5 days, as defined by the STS14). Using 
the national hospital billing database Premier, Yoo et al. recently estimated the economic 
burden of air leaks to be $6,512 higher than those without any air leak complications25. While 
the post-operative phase of ERAS in thoracic surgery involves early post-operative 
mobilization, early removal of chest tubes and drains, and early transition to oral pain 
medications, it does not address air leaks. Therefore, we recommend that thoracic ERAS 
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protocols should include interventions to reduce air leak and consider discharging patients 
with prolonged air leak home earlier with chest tubes placed to a Heimlich valve26. 
 
Finally, a recent study by Horattas et al. suggested that ERAS in colorectal surgery results in 
enhanced patient satisfaction scores and improvements in pain management27. Given the 
multimodal anesthetic and analgesic regimens in ERAS, patient satisfaction scores and pain 
scores are variables that could differ significantly between the pre- and post-ERAS groups. 
The UNC Thoracic Surgery service has collected preliminary data that shows improved 
patient satisfaction scores, decreased opioid equivalents, and better patient pain scores with 
ERAS implementation. Since we did not include these variables for this study, further 
analysis is warranted.  
 
Strengths of this study include the initial comparability of the pre- and post-ERAS groups, 
the large number of variables collected, and minimal missing data. However, our study does 
have limitations, including its small sample size from a single academic medical center. The 
UNC Thoracic Surgery service has significant discharge delay due to patients’ lack of access 
to transportation to get home; this factor may have skewed our data as well. The lack of a 
concurrent control group could also introduce bias given that other factors that contribute to 
health care utilization and complication rates may have changed over the same time frame. 
As previously mentioned, the utilization of VATS is one of the key elements of ERAS in 
thoracic surgery, and having VATS as a common variable for the majority of both the pre- 
and post-ERAS patients could potentially mask the effect of other ERAS elements on 
surgical outcomes9. Lastly, this study focused on objective outcomes (hospital LOS, total 
number of post-operative complications, 30-day readmission and mortality). Future studies 
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could investigate the effect of ERAS on patient-reported outcomes, such as quality of life, 
patient satisfaction scores, and pain scores. 
 
Conclusion: 
 
Our results demonstrated that median hospital LOS, complications, and 30-day readmission 
and mortality did not differ between the pre-ERAS and post-ERAS lung resection groups. 
Thoracic ERAS protocols should include interventions to reduce air leak and consider 
discharging patients with chest tubes placed to a Heimlich valve given that air leaks are 
associated with increased hospital LOS. ERAS has been shown to improve patient 
satisfaction after lung resections – an important consideration in the era of patient-informed 
decisions regarding choice of lung surgeons – and further studies are warranted to continue 
improving lung resection outcomes.
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Table 1. Post-operative events defined by the Society of Thoracic Surgeons1 
Post-operative event Definition 
Unexpected return to OR Primary reason for return to OR was bleeding, anastomotic leak 
following esophageal surgery, bronchopleural fistula, empyema, 
chylothorax requiring surgical ligation of thoracic duct, or other 
Pulmonary complication Air leak >5 days duration, atelectasis requiring bronchoscopy, pleural 
effusion requiring drainage, pneumonia, acute respiratory distress 
syndrome, respiratory failure, bronchopleural fistula, pulmonary 
embolus, pneumothorax, initial vent support >48 hours, reintubation, 
tracheostomy, tracheobronchial injury, or other pulmonary event 
Cardiovascular 
complication 
Atrial arrhythmia requiring medication, ventricular arrhythmia 
requiring medication, myocardial infarct, deep vein thrombosis 
requiring medication, or other cardiovascular event 
Urologic complication Urinary tract infection, urinary retention requiring catheterization, or 
discharged with Foley catheter 
Infection complication Empyema, sepsis, another infection requiring intravenous antibiotics, 
or surgical site infection (none, superficial, deep, organ space 
[empyema, mediastinitis]) 
Hematologic 
complication 
Postoperative packed red blood cells given 
Gastrointestinal 
complication 
Gastric outlet obstruction, ileus, anastomotic leak requiring 
medication only, dilation esophagus within post-operative period, 
conduit necrosis requiring surgery, delayed conduit emptying 
requiring intervention or maintenance of nasogastric drainage >7 days 
post-operatively, Clostridium difficile infection, or other 
gastrointestinal event 
Neurological 
complication 
New central neurological event, recurrent laryngeal nerve paresis or 
paralysis, delirium, or other neurological event 
Miscellaneous 
complication 
Chylothorax requiring drainage or medication, other events requiring 
OR with general anesthesia, unexpected admission to intensive care 
unit, new renal failure per RIFLE criteria 
Abbreviations: OR, operating room; RIFLE criteria, Risk, Injury, Failure, Loss, End stage renal 
disease 
 
1The Society of Thoracic Surgeons (STS). General Thoracic Surgery Database Training Manual. STS National 
Database. https://www.sts.org/sites/default/files/documents/STSThoracicTrainingManualV2_41.master.pdf. 
Accessed June 10, 2018. 
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Table 2. Patient baseline characteristics, stratified by pre- and post- ERAS implementation 
 Before ERAS 
133 (50%) 
After ERAS 
131 (50%) p-value 
Age, in years, median (IQR) 64 (55 – 70) 61 (54 – 68) 0.19 
Male, n (%) 67 (50) 50 (38) 0.05 
Race, n (%)    
White 100 (75) 92 (70) 0.41 
Black 27 (20) 28 (21) 0.88 
Other 6 (5) 11 (8) 0.22 
BMI, median (IQR) 27 (24 – 33) 27 (23 – 31) 0.26 
Comorbidities, n (%)    
Hypertension 73 (55) 60 (46) 0.18 
Congestive heart failure 12 (9) 4 (3) 0.07 
Coronary artery disease 20 (15) 13 (10) 0.26 
Peripheral vascular disease 13 (10) 13 (10) 0.99 
Diabetes, insulin-dependent 6 (5) 3 (2) 0.50 
Renal insufficiency 5 (4) 6 (5) 0.77 
Smoking status, n (%)    
Never 35 (26) 36 (27) 0.89 
Former 69 (52) 72 (55) 0.62 
Current 29 (22) 23 (18) 0.44 
Smoked within 4 weeks of surgery, n (%) 34 (26) 29 (22) 0.56 
Steroid use, n (%) 47 (35) 73 (56) 0.001 
Pre-operative chemotherapy, n (%) 29 (22) 19 (15) 0.15 
Pre-operative radiation, n (%) 27 (20) 15 (11) 0.06 
Prior cardiothoracic surgery, n (%) 15 (11) 17 (13) 0.71 
Primary diagnosis, n (%)    
Benign lung disease 25 (19) 24 (18) 0.99 
Lung cancer 77 (58) 69 (53) 0.46 
Metastatic lung cancer 31 (23) 32 (24) 0.89 
FEV1, %, median (IQR) 83 (72 – 97) 83 (66 – 97) 0.88 
DLCO, %, median (IQR) 70 (57 – 84) 75 (62 – 87) 0.16 
Karnofsky scale, %, median (IQR) 100 (90 – 100) 90 (90 – 100) 0.44 
ASA, n (%)    
1 0 (0) 0 (0) – 
2 13 (10) 12 (9) 0.99 
3 96 (72) 98 (75) 0.68 
4 24 (18) 21 (16) 0.74 
Thoracic revised cardiac risk index, n (%)    
0 104 (78) 1112 (86) 0.15 
1 – 1.5 25 (19) 15 (11) 0.12 
≥2 4 (3) 4 (3) 0.99 
Abbreviations: ERAS, enhanced recovery after surgery; IQR, interquartile range; BMI, 
body mass index; FEV1, forced expiratory volume in 1 second; DLCO, diffusing capacity 
for carbon monoxide 
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Table 3. Intra-operative characteristics, stratified by pre- and post- ERAS implementation 
 Before ERAS 
133 (50%) 
After ERAS 
131 (50%) p-value 
Pre-operative medications, n (%)    
Acetaminophen 7 (5) 102 (78) <0.0001 
Pregabalin 5 (4) 85 (65) <0.0001 
Celecoxib 1 (1) 73 (56) <0.0001 
Procedure, n (%)    
Wedge resection 85 (64) 74 (56) 0.22 
Segmentectomy 0 (0) 1 (1) 0.50 
Lobectomy 46 (35) 56 (43) 0.21 
Bilobectomy 2 (2) 0 (0) 0.50 
Robotic surgery, n (%) 0 (0) 15 (11) <0.0001 
Thoracotomy, n (%) 3 (2) 3 (2) 0.99 
Surgery time, minutes, median (IQR) 121 (67 – 182) 119 (81 – 193) 0.34 
Anesthesia time, minutes, median (IQR) 159 (113 – 217) 173 (126 – 232) 0.18 
Intra-operative medications, n (%)    
Ketorolac 3 (2) 26 (20) <0.0001 
Dexamethasone 44 (33) 69 (53) 0.002 
Vasopressin 9 (7) 51 (39) <0.0001 
Norepinephrine 1 (1) 18 (14) <0.0001 
Regional block type, n (%)    
Intercostal nerve block 90 (68) 102 (78) 0.07 
Epidural 0 (0) 0 (0) – 
Intercostal nerve block + epidural 43 (32) 29 (22) 0.07 
Intercostal nerve block type, n (%)    
Bupivacaine (Marcaine) 133 (100) 37 (28) <0.0001 
Bupivacaine liposome injectable suspension 
(Exparel) 
0 (0) 61 (47) <0.0001 
Bupivacaine (Marcaine) + Bupivacaine 
liposome injectable suspension (Exparel) 
0 (0) 33 (25) <0.0001 
Transfusion, n (%) 0 (0) 0 (0) – 
Total crystalloids, mL, median (IQR) 2000 (900 – 1600) 800 (496 – 1100) <0.0001 
Total colloids, mL, median (IQR) 0 (0 – 0) 250 (0 – 500) <0.0001 
Morphine equivalents, mg, median (IQR) 25 (22 – 32) 20 (15 – 25) <0.0001 
Abbreviations: ERAS, enhanced recovery after surgery; IQR, interquartile range 
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Table 4. Postoperative inpatient outcomes, length of stay, and 30-day readmission, stratified by 
pre- and post- ERAS implementation 
 Before ERAS 
133 (50%) 
After ERAS 
131 (50%) p-value 
Inpatient complications, n (%)    
Pulmonary 20 (15) 20 (15) 0.99 
Cardiovascular 12 (9) 9 (7) 0.65 
Urinary 10 (8) 17 (13) 0.16 
Infection 2 (2) 1 (1) 0.99 
Hemolytic 2 (2) 2 (2) 0.99 
Gastrointestinal 2 (2) 0 (0) 0.50 
Neurological 5 (4) 1 (1) 0.21 
Other 4 (3) 6 (5) 0.54 
Any complication, n (%) 36 (27) 44 (34) 0.28 
30-day mortality, n (%) 0 (0) 2 (2) 0.25 
30-day readmission, n (%) 11 (8) 13 (10) 0.67 
Length of stay, days, median (IQR) 4 (2 – 6) 4 (2 – 6) 0.74 
Abbreviations: ERAS, enhanced recovery after surgery; OR, operating room; IQR, 
interquartile range 
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Table 5. Crude and adjusted effect of ERAS implementation, compared to pre-ERAS 
implementation, on inpatient complications, length of stay, and 30-day readmission 
 Crude  Adjusteda 
 HR (95% CI) p-value  HR (95% CI) p-value 
Inpatient complications      
Pulmonary 1.01 (0.54, 1.87) 0.99  0.83 (0.27, 2.58) 0.75 
Cardiovascular 0.74 (0.31, 1.76) 0.49  0.91 (0.25, 3.29) 0.88 
Urinary 1.74 (0.80, 3.80) 0.17  0.82 (0.24, 2.86) 0.76 
Infection 0.44 (0.04, 4.88) 0.51  NA –  
Hemolytic 1.02 (0.14, 7.20) 0.99  NA –  
Gastrointestinal NA –   NA –  
Neurological 0.19 (0.02, 1.66) 0.13  NA –  
Other 1.52 (0.43, 5.38) 0.52  1.12 (0.14, 8.98) 0.91 
Any complication 1.23 (0.79, 1.92) 0.36  1.23 (0.61, 2.48) 0.56 
30-day mortality NA –   NA –  
30-day readmission 1.21 (0.52, 2.82) 0.65  2.25 (0.61, 8.29) 0.22 
 CIE (95% CI) p-value  CIE (95% CI) p-value 
Length of stay, days 0.18 (-0.86, 1.22) 0.74  0.15 (-1.43, 1.73) 0.85 
Abbreviations: HR, hazard ratio; CI, confidence interval; CIE, change in estimate; NA, not 
analyzable 
a Adjusted for sex, age, prior steroid use, thoracic revised cardiac risk index, intra-operative 
crystalloids, intra-operative colloids, and intra-operative morphine equivalents; age, 
crystalloids, colloids, and morphine equivalents were modeled as restricted cubic splines 
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Introduction 
 
In the 1990s, Henrik Kehlet developed the Enhanced Recovery After Surgery (ERAS) protocol, 
an evidence-based, multidisciplinary peri-operative care model. Key principles of ERAS 
protocols include the following: pre-operative counseling; pre-operative nutrition (minimizing 
peri-operative fasting and carbohydrate loading up to 2 hours pre-operatively); standardized 
multimodal anesthetic and analgesic regimens (epidural and non-opioid analgesia); optimized 
antibiotic and thromboembolic prophylaxis; and early post-operative mobilization. This model 
has been shown to reduce complications and hospital length of stay (LOS), improve 
cardiopulmonary function, and lead to earlier return of bowel function and resumption of 
normal activity. The ERAS protocol was first adapted by the colorectal surgery discipline and 
has since been utilized by other surgical specialties, including vascular surgery, urologic 
surgery, and thoracic surgery1,2. 
 
In the field of thoracic surgery, the prototypical ERATS (Enhanced Recovery After Thoracic 
Surgery) pathway involves three phases. The first is the pre-operative phase, which focuses on 
patient education and smoking cessation. Next, the peri-operative phase incorporates regional 
anesthesia with paravertebral catheters and intercostal nerve blocks, along with minimally-
invasive surgery (such as video-assisted thoracoscopic surgery [VATS] where possible), and 
single chest drain). Finally, the post-operative phase emphasizes the use of incentive spirometry 
(pulmonary toileting), early mobilization within 24 hours, and early chest tube and urinary 
catheter removal. Throughout the three phases, goal-directed fluid therapy and avoidance of 
opiate analgesia is encouraged 2,3. 
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Although the use of ERAS in lung resections began almost 20 years ago, ERATS protocols have 
not been studied as extensively as ERAS pathways in colorectal surgery. Most of the evidence 
for ERATS has been published in case-series reports, but the lack of a control group in these 
studies increases the risk of bias4-6. In 2016, Fiore et al. published a systematic review of six 
comparative studies (five were non-randomized trials) on ERAS in lung resections; however, 
due to the high risk of bias of the included studies, the authors determined that their results were 
inconclusive7. The following year, Li et al. published a systematic review of seven randomized-
controlled trials on this topic, but all of the study participants were from China, Europe, and the 
Middle East8. Recently, a few retrospective cohort studies of ERAS in lung resections have been 
conducted in the United States and Canada, demonstrating that ERATS improves patient 
outcomes after lung resections and provides more cost-effective care9-11. Thus, in this systematic 
review, we aimed to identify recent studies (published in the past five years) and relied on 
existing systematic reviews of older studies to synthesize the evidence as a whole regarding the 
effect of ERAS, in comparison to conventional care, on surgical outcomes of adult patients 
undergoing lung resections. 
 
Methods 
Eligibility criteria 
This systematic review was conducted in compliance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement12. We developed inclusion and 
exclusion criteria with respect to populations, interventions, comparators, outcomes, timing, 
setting, and study designs (shown in Appendix Table 1). Studies enrolling adults (age >18 
years) who underwent lung resections and compared an ERAS intervention with conventional 
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care (no ERAS) were eligible. In terms of outcomes, hospital LOS, 30-day mortality, post-
operative complications (as defined by the Society of Thoracic Surgeons in Table 113) were 
eligible. Only English language studies published within the past five years (2013-2018) were 
included. Eligible study designs included the following: randomized controlled trials (RCTs), 
retrospective cohort studies, prospective cohort studies, case-control studies, and systematic 
reviews (Appendix Table 1). We set the publication time limit as the last five years because we 
aimed to capture the most recent relevant studies. We also included recent systematic reviews 
that covered studies published earlier than the past 5 years in order to assess whether results of 
recent studies were consistent with studies published in the past.  
 
Data Sources and Searches 
We searched PubMed and the Cochrane Library from April 3, 2013 to April 3, 2018, limited to 
English-language articles. We used Medical Subject Headings as search terms when available 
and keywords when appropriate, focusing on terms to describe adult populations who underwent 
lung resections and various synonyms of the ERAS intervention (such as enhanced recovery, 
fast-track, and multimodal optimization) (Appendix Table 2). Similarly, we also searched for 
unpublished studies using ClinicalTrials.gov.  
 
Study Selection 
Two investigators independently reviewed titles, abstracts, and full-text articles using the 
Covidence online platform14 for relevance based on the eligibility criteria described above (and 
shown in Appendix Table 1). Abstracts marked as relevant by both reviewers were reviewed 
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again at the full-text stage. During review of full-text articles, disagreements between reviewers 
were resolved by consensus.  
 
Data Collection Process and Data Items 
We designed and used structured data extraction forms to gather pertinent information from 
each article, including information about the methods and populations, interventions, 
comparators, outcomes, timing, setting, and study designs. The following details were collected 
from each study: publication data (authors and year); setting (nation); source population (total 
sample size, number of patients in ERAS group and control group, type of surgical procedures, 
and operative approach [open thoracotomy vs. VATS]); study design and duration; ERAS 
interventions used; and outcome data (hospital LOS, 30-day mortality, and post-operative 
complications). All data extractions were reviewed for completeness and accuracy by a second 
investigator. Disagreements between data extractors were resolved by consensus.  
 
Risk of Bias Analysis 
To assess the risk of bias in individual studies, we used Cochrane’s risk of bias tool15 to assess 
randomized controlled trials, the Newcastle-Ottawa Scale16 to assess observational studies (both 
prospective and retrospective cohort studies), and the AMSTAR (A MeaSurement Tool to 
Assess systematic Reviews) 217 tool to assess systematic reviews. Two investigators assigned 
the risk of bias for each study, and disagreements were resolved by consensus. We did not 
exclude any studies based on their risk of bias but describe common sources of bias in the 
results section. Heterogeneity in terms of surgical populations (including different types of lung 
resections and surgical approaches [VATS or open thoracotomies]) and ERAS intervention 
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components, together with varying statistical methods and outcome measures across the studies, 
precluded any attempt at meta-analysis. 
 
Results 
Results of Literature Searches 
Upon initial search (see search terms in Appendix Table 2), 314 unique articles were identified. 
Three additional unpublished studies were found in ClinicalTrials.gov. The 317 articles were 
screened by title and abstract, and 254 were excluded based on the aforementioned eligibility 
criteria (Table 1). Full-texts of those marked as potentially relevant (63 articles) were screened 
again using the same eligibility criteria; of these, eight met full eligibility criteria. Reasons for 
exclusion at the full-text stage are shown in Appendix Figure 1.  
 
Study Characteristics 
Of the eight included studies, two were systematic reviews; one included seven RCTs (with a 
meta-analysis)8, and the other included one RCT, one case-control study, two prospective cohort 
studies, and two retrospective cohort studies7. The systematic review by Fiore et al. included all 
studies that compared the effect of ERAS versus conventional care on lung resection outcomes, 
while the one by Li et al. used the same eligibility criteria but only included RCTs. 
 
The six individual studies (6,051 participants in total) identified in our searches for recent 
studies (published between 2015 and 2018) included one RCT, one prospective cohort study, 
and four retrospective cohort studies9-11,18-20. Studies were set in diverse countries, including 
China, Canada, the United States, and the United Kingdom. Individual study sample sizes 
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ranged from 35 to 2886. All studies included a comparison between pre- and post-ERAS 
groups, and all ERAS participants received key components of the thoracic ERAS protocol 
(Appendix Table 3). While most studies enrolled patients who underwent various types of lung 
resections with different surgical approaches (VATS vs. open thoracotomies), one study only 
included open pulmonary lobectomies9, one study only included pneumonectomies18, and two 
studies only included VATS procedures19,20. All studies reported on LOS and complication 
rates, while only 5 studies reported on 30-day readmission rates and 4 reported on 30-day 
mortality rates. 
 
Risk of Bias Analysis 
Most of the studies were determined to have low risk of bias overall. Both systematic reviews 
were deemed to be low risk of bias as their only missing component on the AMSTAR 2 
checklist was discussion regarding funding and conflicts of interest. Selection bias was low in 
all studies: pre- and post-ERAS groups in all studies had similar baseline characteristics, and as 
most of the studies were prospective or retrospective cohort studies that involved EHR review, 
all studies had complete follow-up with all patients accounted for. We rated one RCT as having 
a low-medium risk of bias due to small sample bias (n = 35) and the potential for confounding 
bias, although it had low risk of selection bias, performance bias, detection bias, attrition bias, 
and reporting bias18. There was low risk of measurement bias in these studies that involved EHR 
review. Three studies had a potential for confounding bias, as they did not mention which 
covariates they adjusted for in their statistical analysis10,18,19. Each individual study was 
conducted at a single academic medical center; thus, their results would have low applicability 
to other hospital settings in other nations (Appendix Tables 4-6). 
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Summary of Results 
The two included systematic reviews both reported a significant decrease in hospital LOS in the 
ERAS group (one reported a difference of 1.2-9.1 days), which is consistent with results from 
five of the six individual studies. While one systematic review found no difference in post-
operative complication rates7, the other included a meta-analysis of 486 participants and 
reported a risk ratio (RR) of 0.64 (95% confidence interval [CI], 0.51-0.80)8; similarly, three of 
the six individual studies also described a significant decrease in post-operative complications, 
especially pulmonary complications. None of the studies reported a significant decrease in 30-
day or 90-day readmission or mortality. Notably, one study found no significant differences in 
LOS, post-operative complication rates, 30- and 90-day readmission and mortality between the 
pre- and post-ERAS groups20 (Appendix Table 3). 
 
Discussion 
 
In summary, these studies provide modest evidence that ERAS improves surgical outcomes in 
the field of thoracic surgery. While most studies reported a significant decrease in hospital LOS, 
half of the studies noted a significant decrease in post-operative complications. None of the 
studies, however, found a significant decrease in 30-day or 90-day readmission or mortality. A 
few studies noticed a significant decrease in post-operative pain19 and both societal and medical 
costs in the ERAS group (mean difference in societal cost -$4,396 Canadian per patient10, and 
difference in medical costs of $7,300 Chinese Yuan18); further studies are warranted to study the 
cost and effect of ERAS on patient-reported outcomes such as pain and patient satisfaction 
scores. 
 31 
 
Although these studies have a low risk of bias overall, this body of literature is not without its 
limitations. In the systematic review by Fiore et al., the authors highlight the potential for 
confounding bias in observational studies and thus the need for well-designed RCTs to provide 
conclusive evidence about the effect of ERAS in lung resection outcomes7. Some of these 
studies only included patients who underwent VATS lung resections; since the utilization of 
VATS is one of the key elements of ERAS in thoracic surgery, Brunelli et al. discuss that 
operating with VATS in both pre- and post-ERAS patients could potentially mask the effect of 
other ERAS elements on surgical outcomes20. The different surgical populations (including 
different types of lung resections and surgical approaches [VATS or open thoracotomies]) and 
ERAS intervention components in these studies, together with varying statistical methods and 
outcome measures across the studies, renders it difficult to perform a meta-analysis.  
 
Conclusion 
Although the reviewed studies do not clearly establish the magnitude of benefit of ERAS on 
post-operative hospital LOS, complications, 30- and 90-day readmission and mortality, the 
results are promising given that most studies consistently found significantly decreased LOS 
with ERAS implementation. Future research, including future RCTs, should be conducted with 
larger sample sizes to better determine the association between ERAS and surgical outcomes of 
lung resections. Studies regarding the effect of ERAS on patient-reported outcomes such as pain 
scores and patient satisfaction scores are also warranted. 
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Appendix Table 1. Systematic review eligibility criteria 
 
PICOTSS Inclusion Criteria Exclusion Criteria 
Population(s) Patients age >18 who 
undergo lung resections (+/- 
video-assisted thoracoscopic 
surgery [VATS]) 
Children age <18, pregnant 
women, adults who undergo 
other types of thoracic 
surgery (such as 
esophagectomies) 
Interventions Enhanced Recovery After 
Surgery (ERAS) protocol 
Conventional care (no ERAS 
intervention); just single 
components of ERAS (not all 
key elements of ERAS 
protocol) 
Comparators ERAS vs. pre-ERAS protocol 
for thoracic surgery 
No comparison (all patients 
had ERAS intervention); non-
concordant historical controls 
Outcomes Hospital length of stay 
(LOS), 30-day mortality, 
post-operative complications 
(as defined by the STS in 
Table 11) 
All other outcomes 
Timing Studies within the last 5 years 
(2013-2018) 
Studies older than 2013 
Settings Inpatient hospital settings Other non-hospital settings 
Study Designs Randomized controlled trials, 
retrospective cohort studies, 
prospective cohort studies, 
case-control studies, 
systematic reviews 
Non-systematic reviews, case 
reports, case series, cross-
sectional studies, and 
modelling studies (such as 
cost-effectiveness analyses) 
1The Society of Thoracic Surgeons (STS). General Thoracic Surgery Database Training Manual. STS National 
Database. https://www.sts.org/sites/default/files/documents/STSThoracicTrainingManualV2_41.master.pdf. 
Accessed June 10, 2018. 
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Appendix Table 2. Systematic review detailed search strategy 
 
Database Search Terms 
PubMed (("enhanced recovery" OR "fast-track" OR fasttrack OR 
"accelerated rehabilitation" OR ERAS OR FTS OR "rapid 
recovery" OR "early recovery" OR "multimodal optimization" 
OR "early mobilization") AND (lung OR lungs OR pulmon*) 
AND (resect* OR surger* OR surgic* OR operation* OR 
operativ*)) AND "last 5 years"[PDat] AND English[lang] 
 
Cochrane Library1 ("enhanced recovery" OR "fast-track" OR fasttrack OR 
"accelerated rehabilitation" OR ERAS OR FTS OR "rapid 
recovery" OR "early recovery" OR "multimodal optimization" 
OR "early mobilization") AND (lung OR lungs OR pulmon*) 
AND (resect* OR surger* OR surgic* OR operation* OR 
operativ*) 
 
1Note: Also added search limit of past 5 years under “Title/Abstract” drop-down menu. 
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Appendix Figure 1. PRISMA flow diagram of disposition of articles1 
 
 
 
1Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-
analyses of Studies that Evaluate Health Care Interventions: Explanation and Elaboration. Ann Intern Med. 
2009;151:W-65--W-94. 
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Appendix Table 3. Summary characteristics of included studies    
 
# Referenc
e 
Setting Source population Study design and 
duration 
ERAS interventions used Outcomes reported 
1. Fiore et 
al. 2016 
Systematic 
review that 
included 2 
studies from 
the United 
States (1997 
and 1998), 3 
studies from 
Europe 
(2008-2012), 
and 1 study 
from Japan 
(2006) 
Total sample size was 1612 participants 
(821 ERAS vs. 791 control). Sample 
size of included studies ranged from 
58-464 (most studies had half of sample 
exposed to ERAS). 2 studies involved 
only patients undergoing lobectomy, 
and 4 studies involves a variety of lung 
resection procedures (ranging from 
wedge resection to pneumonectomy). 
One study included only VATS 
procedures, and one study only 
included thoracotomies. 
Systematic review 
(included 1 RCT, 2 
retrospective cohort 
studies, 2 
prospective cohort 
studies, and 1 case-
control study).  
Most included studies had the following ERAS 
components: pre-operative patient 
education/counseling and prophylactic antibiotics, 
intra-operative epidural anesthesia/analgesia, and post-
operative standardized chest tube management, early 
removal of epidural catheter, early removal of oxygen 
support, early feeding, and early mobilization. 
The 1 RCT reported no differences in hospital LOS, but 
all the nonrandomized studies reported decreased LOS 
(difference 1.2-9.1 days). There were no significant 
differences in readmissions, overall complications, and 
mortality rates. Two nonrandomized studies also reported 
decreased hospital costs in the ERAS group. 
2. Li et al. 
2017 
Systematic 
review that 
included 4 
studies from 
China (2010-
2017), 2 
studies from 
Europe 
(2008 and 
2017), and 1 
study from 
the Middle 
East (2011). 
Total sample size was 486 (243 ERAS 
vs. 243 control). Majority of patients 
were diagnosed with primary non small 
cell lung cancers (n=472). 326 patients 
(67%) underwent lobectomy, 78 (16%) 
underwent pneumonectomy, and 82 
(17%) underwent sublobar resections. 
Most of the patients had standard 
posterolateral thoractomy (n=392, 
81%), and only 94 (19%) had VATS 
procedures. 
Systematic review 
(included 7 RCTs); 
study duration 
ranged from 1-3 
years 
Most included studies had the following ERAS 
components: pre-operative patient 
education/counseling and intensive pulmonary 
physiologic therapy, post-operative epidural 
analgesia/nonsteroidal analgesic painkillers, 
intravenous fluid restriction, early oral feeding, and 
early ambulation. 
Meta-analysis demonstrated that ERAS group had 
significantly lower morbidity rates (RR=0.64; p<0.001), 
especially the rates of pulmonary (RR=0.43; p<0.001) and 
surgical complications (RR=0.46; p=0.010). There was no 
significant difference in inpatient mortality or 
cardiovascular complications. Qualitatively, most studies 
reported significantly shorter hospital LOS, ICU stay, and 
decreased hospitalization costs in the ERAS group. 
3. Madani 
et al. 
2015 
Canada 
(single 
academic 
center) 
Sample size n = 234 (107 ERAS vs. 
127 control). Only open pulmonary 
lobectomies. 
Retrospective 
cohort study 
(August 2011-
October 2013) 
ERAS intervention included pre-operative patient 
education/counselling, opioid-sparing pain control, 
preferred extubation in the OR or PACU, early and 
structured mobilization, early feeding and optimization 
of nutritional status, standardized drain management, 
and target discharge with written patient goals for each 
post-operative day. 
The ERAS group had decreased LOS (median, 6 [IQR, 5–
7] vs 7 [6–10] days; p<0.05), total complications (40 
[37%] vs 64 [50%]; p<0.05), urinary tract infections (3 
[3%] vs 15 [12%]; p<0.05), and chest tube duration 
(median, 4 [IQR, 3–6] vs 5 [4–7] days; p<0.05), with no 
difference in readmissions (7 [7%] vs 6 [5%]; p<0.05) or 
chest tube reinsertion (4 [4%] vs 6 [5%]; p<0.05). 
Decreased LOS was driven by patients without 
complications (median, 5 [IQR, 4–6] vs 6 [5–7] days; 
p<0.05).  
4. Paci et 
al. 2017 
Canada 
(single 
academic 
center) 
Sample size n = 133 (75 ERAS vs. 58 
control). All elective lung resections 
(except pneumonectomies and extended 
resections). 
Prospective 
before/after cohort 
study (August 
2011-August 2013) 
ERAS intervention included pre-operative patient 
education/counselling, opioid-sparing pain control, 
preferred extubation in the OR or PACU, early and 
structured mobilization, early feeding and optimization 
of nutritional status, standardized drain management, 
and target discharge with written patient goals for each 
post-operative day. 
The ERAS group had shorter median (IQR) LOS (4 [3 to 
6] days vs 6 [4 to 9] days, p<0.01), decreased total 
complications (32% vs 52%, p=0.02), and decreased 
pulmonary complications (16% vs 34%, p=0.01, with no 
difference in readmissions. There was a trend towards less 
post-discharge caregiver burden for the ERAS group (53 
± 90 hours vs 101 ± 252 hours, p=0.17. Overall societal 
costs were lower in the ERAS group (mean difference per 
patient: –$4,396 Canadian; 95% confidence interval –
$8,674 to $618 Canadian).  
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5. Van 
Haren et 
al. 2018 
United States 
(single 
academic 
medical 
center) 
Sample size n = 2886 (324 ERAS vs. 
929 transitional period vs. 1615 
control). Included patients undergoing 
pulmonary resection for primary lung 
cancer (both VATS and open 
thoracotomy). 
Retrospective 
cohort study 
(January 2006-
December 2016) 
ERAS intervention included pre-operative patient 
education, preventive analgesia, peri-operative 
steroids, opioid-sparing analgesia, total intravenous 
anesthesia, goal-directed fluid therapy, regional 
analgesia with pre-incisional posterior intercostal nerve 
blockage and local wound infiltration with long-acting 
liposomal bupivacaine, early ambulation, early oral 
intake, and early chest tube removal. 
For all patients, LOS decreased in both ERAS and 
transitional periods compared to pre-ERAS (4[3] vs. 4[3] 
vs. 5[3] days, p<0.001). Pulmonary complications were 
decreased with ERAS compared to transitional and Pre-
ERAS (19.9% vs. 28.2% vs. 28.7%, p=0.004). Cardiac 
complications decreased with ERAS (12.3% vs. 13.1% 
vs. 18.1%, p=0.001). There was less thoracic epidural use 
(2.9% vs. 44.5% vs. 75.5%, p<0.001). There were no 
differences in hospital readmission or mortality rates. 
Following thoracotomy, ERAS was associated with 
decreased LOS, less ICU readmission, and decreased 
frequency of pneumonia, atrial arrhythmias, and need for 
home oxygen (all p<0.05). ERAS was independently 
associated with decreased pulmonary (p=0.046) and 
cardiac complications (p=0.001) on logistic regression 
after thoracotomy, but not minimally invasive surgery.  
6. Dong et 
al. 2017 
China (single 
academic 
medical 
center) 
Sample size n = 35 (17 ERAS vs. 18 
control). All patients with non small 
cell lung cancer and only 
pneumonectomies. 
Randomized 
controlled trial 
(June 2012-March 
2014). 
ERAS intervention included pre-operative patient 
education, pre-operative carbohydrate diet, intra-
operative warming, post-operative analgesia with 
patient-controlled epidural analgesia and oral 
nonsteroidal analgesic painkillers, early post-operative 
feeding, chewing gum to promote bowel movements, 
early removal of urinary catheter, and early post-
operative ambulation. 
In the ERAS group, latency to the first postoperative 
flatus (1.5 ± 0.6 versus 3. 1 ± 0.8 s in controls, p<0.0001), 
C-reactive protein (71.36 ± 5.48 versus 80.71 ± 8.32 mg/L 
in at POD 7, p<0.0001), the length of hospital stay (18.1 ± 
1.4 versus 27.4 ± 6.6 days, p<0.0001), and the medical 
costs (29.9 ± 2.7 versus 37.2 ± 3.6 thousand Chinese 
Yuan, p<0.0001) were significantly reduced. The ERAS 
group also had a relatively lower postoperative 
complication rate (23.5% of 17 versus 33.3% of 18 in 
control group) although it was statistically insignificant.  
7. Huang et 
al. 2018 
China (single 
academic 
medical 
center) 
Sample size n = 83 (38 ERAS vs. 45 
control). All patients with non small 
cell lung cancer and only uni-portal 
VATS procedures. 
Retrospective 
cohort study 
(January 2016-
February 2017). 
ERAS intervention included pre-operative patient 
education, alcohol and tobacco cessation 2-4 weeks 
pre-operatively, pre-operative respiratory function 
exercises, pre-operative carbohydrate loading, 
prophylactic antibiotics, intra-operative warming, intra-
operative anesthesia (with general anesthesia, local 
anesthesia, and intercostal nerve block), goal-directed 
fluid therapy, post-operative analgesia (opioid-sparing 
and oral non-steroidal anti-inflammatory analgesics), 
post-operative aerosol inhalation with respiratory 
function training, early ambulation, and early removal 
of urinary catheter and chest tubes. 
The ERAS group had better visual analogue scale (VAS, 
to estimate wound pain) on the third post-operative day 
(3.11 vs. 3.69; p=0.003), shorter chest tube duration (5.26 
vs. 7.02; p=0.021), and shorter length of hospital stay 
(6.58 vs. 8.69; p=0.024). There were no significant 
differences between the groups in terms of operative 
duration, number of lymph nodes retrieved, blood loss, 
VAS on the first post-operative day, or complication rate.  
8. Brunelli 
et al. 
2017 
United 
Kingdom 
(single 
academic 
medical 
center) 
Sample size n = 600 (235 ERAS vs. 
365 control). 561 VATS lobectomies 
and 39 VATS segmentectomies.  
Retrospective 
cohort study (April 
2014-January 
2017). 
ERAS intervention included pre-operative patient 
education, pre-operative carbohydrate loading, pre-
operative and intra-operative warming, no prolonged 
fasting, post-operative discharge when criteria met, 
early mobilization, early oral feeding, nausea and 
vomiting prevention, goal-directed fluid therapy, and 
opioid-sparing analgesia. 
Between the pre- and post-ERAS groups, there were no 
significant differences in LOS (ERAS median 5 days vs 
pre–ERAS 4, p=0.44), cardiopulmonary complication 
rates (22.6% vs 22.4%, p=0.98), 30-day mortality rates 
(3.8% vs 2.2%, p=0.31), and 90-day mortality rates (4.7% 
vs 3.0%, p=0.37). No significant differences were noted 
in terms of 30-day (7.2% vs 7.4%, p=0.94) or 90-day 
readmission rates (9.8% vs 12.3%, p=0.34). The risk-
adjusted cardiopulmonary morbidity rates were similar in 
the 2 periods (p=0.76), whereas the risk-adjusted 30-day 
mortality was significantly higher in the ERAS period 
compared with the pre–ERAS mortality (p=0.0004).  
       
Abbreviations: RCT, randomized controlled trials; ERAS, enhanced recovery after surgery; RR, risk ratio; IQR, interquartile range; OR, operating room; PACU, post-anesthesia care unit; ICU, intensive care unit; LOS, length 
of stay; VATS, video-assisted thoracoscopic surgery 
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Appendix Table 4. Risk of bias analysis for randomized controlled trials1 
	 	  
# Reference 
Random Sequence 
Generation 
Allocation 
concealment 
Blinding of participants 
and personnel 
Incomplete 
outcome 
assessment 
Selective 
reporting Other bias 
6. Dong et 
al. 2017 
Low risk: Computer-
generated block 
randomization 
initiated by a data 
manager in the 
respiratory research 
group 
Low risk: 
Sequential 
opaque 
envelopes 
Low risk: Both the 
surgeon and the thoracic 
research assistant 
interviewing potential 
candidates for the study 
were blind to the 
randomization code. 
When evaluating 
outcomes, a thoracic 
research assistant blinded 
to intervention was 
assigned to ensure double 
blind and minimize 
potential bias. 
Low risk: 
Complete follow-
up with all 
patients 
accounted for 
(chart review) 
Low risk: All 
pre-specified 
outcomes 
were 
reported 
Low-medium 
risk: Small 
sample size 
bias (n = 35). 
Also potential 
for 
confounding 
bias, as they 
did not 
mention which 
covariates 
were adjusted 
for. 
 
1Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMI. 
2011;343:d5928. doi: 10.1136/bmj.d5928.
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Appendix Table 5. Risk of bias analysis for observational studies1 
# Reference 
Representativeness 
of exposed cohort 
Selection of 
non-exposed 
cohort 
Ascertainment 
of exposure 
Demonstration 
outcome of 
interest was 
not present at 
start of study 
Comparability of cohorts 
on basis of design or 
analysis 
Assessment of 
outcome 
Follow-up long 
enough for 
outcomes to 
occur 
Adequacy of 
follow-up of 
cohorts 
Total category 
scores 
3. Madani 
et al. 
2015 
Truly 
representative 
of the average 
Drawn from 
same 
community 
as the 
exposed 
cohort 
Secure 
record 
(EHR) 
Yes Pre- and post-ERAS 
groups were very 
similar in baseline 
characteristics. 
Adjusted for age, 
gender, BMI, and 
ASA score. 
Data collected 
from both paper 
and electronic 
hospital charts.  
Yes - 30-day 
post-
operative 
outcomes 
Complete 
follow-up - all 
subjects 
accounted for 
(retrospective 
chart review) 
Selection: 4/4; 
Comparability: 
2/2; Outcome: 
3/3 
4. Paci et 
al. 2017 
Truly 
representative 
of the average 
Drawn from 
same 
community 
as the 
exposed 
cohort 
Secure 
record 
(EHR) 
Yes Pre- and post-ERAS 
groups were very 
similar in baseline 
characteristics. Did not 
mention which 
covariates were 
adjusted for. Subgroup 
analyses were 
performed to 
investigate economic 
effect of ERAS based 
on employment status, 
operative approach 
(VATS vs. open 
thoracotomy), 
resection (anatomy 
and non-anatomic), 
and post-operative 
complications. 
Data collected 
from electronic 
hospital charts 
and patient 
questionnaires. 
Unit costs were 
obtained from 
hospital finance 
department or 
from provincial 
health ministry 
records. 
Physician billing 
fees were 
ascertained using 
the fee schedule 
from the 
province of 
Quebec in 2013. 
Yes - 30-day 
and 90-day 
post-
operative 
outcomes 
Complete 
follow-up - all 
subjects 
accounted for 
(chart review) 
Selection: 4/4; 
Comparability: 
1/2; Outcome: 
3/3 
5. Van 
Haren et 
al. 2018 
Truly 
representative 
of the average 
Drawn from 
same 
community 
as the 
exposed 
cohort 
Secure 
record 
(EHR) 
Yes Pre- and post-ERAS 
groups were very 
similar in baseline 
characteristics. 
Adjusted for age, 
gender, time period 
(pre-ERAS, transition, 
and ERAS), 
performance status, 
readmission to ICU, 
extent of surgical 
resection, surgical 
approach, utilization 
Data collected 
from thoracic 
surgery database 
(prospectively 
maintained by 
thoracic surgery 
team members 
and reviewed 
monthly by 
departmental 
data analyst to 
ensure accuracy; 
data is also 
Yes - 30-day 
post-
operative 
outcomes 
Complete 
follow-up - all 
subjects 
accounted for 
(retrospective 
chart review) 
Selection: 4/4; 
Comparability: 
2/2; Outcome: 
3/3 
 42 
of epidural catheter, 
extent of surgical 
resection, pathologic 
stage, ASA score, and 
pre-existing COPD. 
submitted to STS 
database and 
subject to 
independent 
review for 
accuracy). 
7. Huang 
et al. 
2018 
Truly 
representative 
of the average 
Drawn from 
the same 
community 
as the 
exposed 
cohort 
Secure 
record 
(HER) 
Yes Pre- and post-ERAS 
groups were very 
similar in baseline 
characteristics. Did not 
mention which 
covariates were 
adjusted for. 
Data collected 
from electronic 
hospital charts. 
Unclear how 
long patients 
were 
followed for 
post-
operative 
complicatio
ns – authors 
stated short 
follow-up 
time. 
Complete 
follow-up – all 
subjects 
accounted for 
(retrospective 
chart review) 
Selection: 4/4; 
Comparability: 
1/2; Outcome: 
3/3 
8. Brunelli 
et al. 
2017 
Truly 
representative 
of the average 
Drawn from 
same 
community 
as the 
exposed 
cohort 
Secure 
record 
(EHR) 
Yes Pre- and post-ERAS 
groups were very 
similar in baseline 
characteristics. 
Adjusted for age, sex, 
BMI, FEV1, DLCO, 
presence of underlying 
coronary artery 
disease, 
cerebrovascular 
disease, diabetes, 
performance score, 
and duration of 
surgery. 
Data collected 
from a 
prospectively 
maintained 
quality-
improvement 
institutional 
database. 
Yes - 30-day 
and 90-day 
post-
operative 
outcomes 
Complete 
follow-up - all 
subjects 
accounted for 
(retrospective 
chart review) 
Selection: 4/4; 
Comparability: 
2/2; Outcome: 
3/3 
 
Abbreviations: EHR, electronic health record; ASA, American Society of Anesthesiologists; BMI, body mass index; COPD, chronic obstructive pulmonary disease; STS, Society 
of Thoracic Surgeons; FEV1, forced expiratory volume in 1 second; DLCO, diffusing capacity of carbon monoxide 
 
 
1Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. The Ottawa Hospital Research 
Institute. doi:10.2307/632432. 
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Appendix Table 6. Risk of bias analysis for systematic reviews1 
	 	
  
Fiore et al. 
2016 
Li et al. 
2017 
Did the research questions and inclusion criteria for the review include 
components of PICO1? 
Yes Yes 
Did the report of the review contain an explicit statement that the review 
methods were established prior to the conduct of the review and did the 
report justify any significant deviations from the protocol? 
Yes Yes 
Did the review authors explain their selection of the study designs for 
inclusion in the review? 
Yes Yes 
Did the review authors use a comprehensive literature search strategy? Yes Yes 
Did the review authors perform study selection in duplicate? Yes Yes 
Did the review authors perform data extraction in duplicate? Yes Yes 
Did the review authors provide a list of excluded studies and justify the 
conclusions? 
Yes Yes 
Did the review authors describe the included studies in adequate detail? Yes Yes 
Did the review authors use a satisfactory technique for assessing the risk 
of bias in individual studies that were included in the review? 
Yes - 
Cochrane 
ROB tool 
Yes - 
Jadad 
score 
Did the review authors report on the sources of funding for the studies 
included in the review? 
No No 
If meta-analysis was performed did the review authors use appropriate 
methods for statistical combination of results? 
N/A Yes 
If meta-analysis was performed, did the review authors assess the 
potential impact of risk of bias in individual studies on the results of the 
meta-analysis or other evidence synthesis? 
N/A Yes 
Did the review authors account for risk of bias in individual studies when 
interpreting/discussing the results of the review? 
Yes Yes 
Did the review authors provide a satisfactory explanation for, and 
discussion of, any heterogeneity observed in the results of the review? 
Yes Yes 
If they performed quantitative synthesis did the review authors carry out 
an adequate investigation of publication bias (small study bias) and 
discuss its likely impact on the results of the review? 
N/A Yes 
Did the review authors report any potential sources of conflict of interest, 
including any funding they received for conducting the review? 
Yes No 
Abbreviations: PICO, Population, intervention, comparator group, outcome; ROB, Risk of bias 
1Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised 
or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. 
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